0000000000285229

AUTHOR

Margaret L. Gulley

showing 3 related works from this author

Abstract 4246: Associations of Epstein-Barr virus (EBV)-positive gastric cancer with circulating mediators of inflammation and immune response

2017

Abstract Epstein-Barr virus (EBV) positivity defines one of four major molecular types of gastric cancer in The Cancer Genome Atlas (TCGA). However, viral status is not routinely determined in clinical practice and tumor samples are not generally collected in epidemiologic research. Histologically, EBV-positive gastric cancer is characterized by prominent inflammatory infiltrate. In molecular analyses from TCGA, EBV-positive gastric cancer had significantly higher expression of several chemokines, chemokine receptors and programmed death-ligand 1 (PD-L1) as compared to other molecular types combined. We hypothesized that EBV tumor status may also be reflected in profiles of circulating chem…

Cancer ResearchChemokinebiologybusiness.industryInflammationIn situ hybridizationmedicine.disease_causeEpstein–Barr virusVirusTumor StatusChemokine receptorImmune systemOncologyImmunologybiology.proteinMedicinemedicine.symptombusinessCancer Research
researchProduct

Associations of epstein-barr virus-positive gastric adenocarcinoma with circulating mediators of inflammation and immune response

2018

Epstein-Barr virus (EBV)-positive gastric adenocarcinoma exhibits locally intense inflammation but systemic manifestations are uncertain. Our study examined whether circulating mediators of inflammation and immune response differ by tumor EBV status. From a Latvian series of 302 gastric cancer cases, we measured plasma levels of 92 immune-related proteins in the 28 patients with EBV-positive tumors and 34 patients with EBV-negative tumors. Eight markers were statistically significantly higher with tumor EBV positivity: chemokine C-C motif ligand (CCL) 20 (Odds Ratio (OR) = 3.6; p-trend = 0.001), chemokine C-X-C motif ligand 9 (OR = 3.6; p-trend = 0.003), programmed death-ligand 1 (PD-L1; OR…

0301 basic medicinePD-L1ChemokineCancer ResearchInflammationlcsh:RC254-282CCL803 medical and health sciencesImmune systemEBVPD-L1medicineCCL11Inflammationbiologybusiness.industryCommunicationCCL19lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune checkpoint3. Good health030104 developmental biologyOncologyImmunologybiology.proteinmedicine.symptomChemokinesbusinessGastric cancerCancers
researchProduct

Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia

2019

Objective Epstein-Barr virus (EBV)-associated gastric cancer has been proposed to be a distinct gastric cancer molecular subtype. The prognostic significance of EBV infection in gastric cancer remains unclear and needs further investigation. Our study aimed to analyze EBV-positive and EBV-negative gastric cancer patients regarding their personal and tumor-related characteristics, and compare their overall survival. Methods Gastric cancer patients consecutively treated at the Riga East University Hospital during 2009-2016 were identified retrospectively. Tumor EBV status was determined by in-situ hybridization for EBV-encoded RNA (EBER). Information about clinicopathological characteristics …

AdultMalemedicine.medical_specialtyEpstein-Barr Virus InfectionsComorbidityKaplan-Meier EstimateAdenocarcinomaGastroenterologyHospital recordsArticle03 medical and health sciencesYoung Adult0302 clinical medicineAge DistributionStomach NeoplasmsInternal medicinehemic and lymphatic diseasesmedicineHumansStage (cooking)Sex DistributionAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overHepatologyStage I Gastric Cancerbusiness.industryHazard ratioSmokingGastroenterologyCancerEpstein-Barr Virus PositiveMiddle AgedOverweightUniversity hospitalmedicine.diseasePrognosisLatviaConfidence intervalSurvival Rate030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleNeoplasm Gradingbusiness
researchProduct